These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 9085326

  • 21. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
    Flint OP, Masters BA, Gregg RE, Durham SK.
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
    [Abstract] [Full Text] [Related]

  • 22. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J, Willekes-Koolschijn N, Koomans H, Van Tol A, Geelhoed-Mieras T, Crommelin D, Van Bloois L, Krajnc-Franken M, Cohen L, Griffioen M.
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [Abstract] [Full Text] [Related]

  • 23. Effect of pravastatin on impaired endothelium-dependent relaxation induced by lysophosphatidylcholine in rat aorta.
    Deng HF, Xiong Y.
    Acta Pharmacol Sin; 2005 Jan; 26(1):92-8. PubMed ID: 15659120
    [Abstract] [Full Text] [Related]

  • 24. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin.
    Thelen KM, Rentsch KM, Gutteck U, Heverin M, Olin M, Andersson U, von Eckardstein A, Björkhem I, Lütjohann D.
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1146-52. PubMed ID: 16282522
    [Abstract] [Full Text] [Related]

  • 25. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion.
    Joyce M, Kelly C, Winter D, Chen G, Leahy A, Bouchier-Hayes D.
    J Surg Res; 2001 Nov; 101(1):79-84. PubMed ID: 11676559
    [Abstract] [Full Text] [Related]

  • 26. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats.
    Wout ZG, Pec EA, Maggiore JA, Williams RH, Palicharla P, Johnston TP.
    J Parenter Sci Technol; 1992 Nov; 46(6):192-200. PubMed ID: 1474430
    [Abstract] [Full Text] [Related]

  • 27. Effects of propionic acid and pravastatin on HMG-CoA reductase activity in relation to forestomach lesions in the rat.
    Bueld JE, Bannenberg G, Netter KJ.
    Pharmacol Toxicol; 1996 Apr; 78(4):229-34. PubMed ID: 8861780
    [Abstract] [Full Text] [Related]

  • 28. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
    Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K.
    Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
    [Abstract] [Full Text] [Related]

  • 29. [Effect of the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A reductase, pravastatin and simvastatin, on colony formation by hematopoietic progenitor cells].
    Kunitama M, Komatsu N, Miura Y.
    Rinsho Ketsueki; 1996 Nov; 37(11):1314-7. PubMed ID: 8960668
    [Abstract] [Full Text] [Related]

  • 30. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver.
    Keller RK, Zhao Z, Chambers C, Ness GC.
    Arch Biochem Biophys; 1996 Apr 15; 328(2):324-30. PubMed ID: 8645011
    [Abstract] [Full Text] [Related]

  • 31. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors unmask cryptic regulatory mechanisms.
    Lopez D, Chambers CM, Ness GC.
    Arch Biochem Biophys; 1997 Jul 01; 343(1):118-22. PubMed ID: 9210653
    [Abstract] [Full Text] [Related]

  • 32. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier.
    Tsuji A, Saheki A, Tamai I, Terasaki T.
    J Pharmacol Exp Ther; 1993 Dec 01; 267(3):1085-90. PubMed ID: 8263769
    [Abstract] [Full Text] [Related]

  • 33. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase activity is inhibited by cholesterol and up-regulated by sitosterol in sitosterolemic fibroblasts.
    Honda A, Salen G, Honda M, Batta AK, Tint GS, Xu G, Chen TS, Tanaka N, Shefer S.
    J Lab Clin Med; 2000 Feb 01; 135(2):174-9. PubMed ID: 10695663
    [Abstract] [Full Text] [Related]

  • 34. Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
    Kumai T, Oonuma S, Matsumoto N, Takeba Y, Taniguchi R, Kamio K, Miyazu O, Koitabashi Y, Sekine S, Tadokoro M, Kobayashi S.
    Life Sci; 2004 Mar 12; 74(17):2129-42. PubMed ID: 14969717
    [Abstract] [Full Text] [Related]

  • 35. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
    Flint OP, Masters BA, Gregg RE, Durham SK.
    Toxicol Appl Pharmacol; 1997 Jul 12; 145(1):99-110. PubMed ID: 9221829
    [Abstract] [Full Text] [Related]

  • 36. Effects of single administration of pravastatin sodium on hepatic cholesterol metabolism in rats.
    Fujioka T, Tsujita Y.
    Eur J Pharmacol; 1997 Apr 04; 323(2-3):223-8. PubMed ID: 9128842
    [Abstract] [Full Text] [Related]

  • 37. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans.
    Kallien G, Lange K, Stange EF, Scheibner J.
    Hepatology; 1999 Jul 04; 30(1):14-20. PubMed ID: 10385633
    [Abstract] [Full Text] [Related]

  • 38. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH, Choi JS, Choi DH.
    Pharmacology; 2011 Jul 04; 88(1-2):1-9. PubMed ID: 21709429
    [Abstract] [Full Text] [Related]

  • 39. Mechanisms underlying the impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in aged rat liver.
    Pallottini V, Montanari L, Cavallini G, Bergamini E, Gori Z, Trentalance A.
    Mech Ageing Dev; 2004 Sep 04; 125(9):633-9. PubMed ID: 15491682
    [Abstract] [Full Text] [Related]

  • 40. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans.
    Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, Sugiyama Y.
    Drug Metab Dispos; 2010 Feb 04; 38(2):215-22. PubMed ID: 19875501
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.